文献速递肺结节与肺癌呼吸道感染

肺癌三药联合治疗相关结核病首例报告

Tuberculosis associated with Triplet therapy for lung cancer.
PubMed 文献 · Thorax · 2020-05-14

本文报告首例肺癌三药联合治疗(化疗与免疫治疗同时进行)相关结核病,于治疗开始后仅44天发生。作者指出三药联合已成为不可手术肺癌的标准一线治疗,结核再激活日益被认为是免疫检查点抑制的不良反应,但送检诊断样本对避免漏诊至关重要。

要点

  • 三药联合治疗是不可手术肺癌的标准一线治疗。
  • 免疫检查点抑制相关的结核再激活需送检样本以避免漏诊。
  • 新型癌症免疫治疗挑战结核宿主-病原体相互作用的传统观点。

核心结论

  • 报告首例肺癌三药联合治疗相关结核病,于治疗开始后44天发生。

主要发现

  • 结核病在三药联合治疗开始后44天发生。
  • 三药联合治疗现为不可手术肺癌的标准一线治疗。
  • 结核再激活日益被认为是免疫检查点抑制的不良反应。
  • 送检诊断样本对避免漏诊至关重要。
  • 文献报告的病例可能仅为冰山一角。

临床怎么用

  • 对使用抗PD-1药物治疗后出现新肺部病灶的肺癌患者,应送检诊断样本以排除结核。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report the first case of TB associated with triplet therapy (chemotherapy and immunotherapy concurrently) for lung cancer, developing just 44 days after treatment initiation. We feel that several important learning points arise from the discussion that are likely to be very relevant to the broad readership of Thorax, and have important clinical and scientific implications. In the three discussion paragraphs, we highlight that: 1) Triplet therapy is now standard first-line treatment for inoperable lung cancer. 2) TB reactivation is increasingly recognised as an adverse effect of immune checkpoint inhibition, but sending diagnostic samples is critical to avoid a missed diagnosis. 3) These insights from novel cancer immunotherapies are challenging the traditional views of the host-pathogen interaction in TB, with wide implications for future control strategies. We propose that the cases reported in the literature are likely to be the tip of the iceberg as most people with lung cancer managed with antiprogrammed death-1 agents who develop new lung lesions will be treated with standard antibiotics and then palliated when they do not respond.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Crawley D, Breen RA, Elkington PT, et al. Tuberculosis associated with Triplet therapy for lung cancer. Thorax. 2020. PMID: 32409610. doi:10.1136/thoraxjnl-2019-213913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。